Axsome Therapeutics (AXSM) Net Cash Flow Growth (1y) (2016 - 2026)
Axsome Therapeutics (AXSM) Net Cash Flow Growth (1y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Axsome Therapeutics | 12.28 Bn | 11.98 Bn | 176.48 Mn | -23.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.43% |
| Dec 31, 2025 | 80.49% |
| Sep 30, 2025 | 90.48% |
| Jun 30, 2025 | 113.34% |
| Mar 31, 2025 | 73.62% |
| Dec 31, 2024 | 60.53% |
| Sep 30, 2024 | 156.86% |
| Jun 30, 2024 | -108.28% |
| Mar 31, 2024 | -219.88% |
| Dec 31, 2023 | -13.84% |
| Sep 30, 2023 | -113.33% |
| Jun 30, 2023 | 1,784.62% |
| Mar 31, 2023 | 2,687.71% |
| Dec 31, 2022 | 5.23% |
| Sep 30, 2022 | 679.50% |
| Jun 30, 2022 | 51.73% |
| Mar 31, 2022 | 90.82% |
| Dec 31, 2021 | -52.30% |
| Sep 30, 2021 | -327.74% |
| Jun 30, 2021 | -253.49% |